CIK 0001839970 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BlossomHill Therapeutics, Inc.
Sign in to watch- Ticker
- BLSM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851578711
- Phone
- 858-732-3880
- Business address
- 10255 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Regulation FD disclosure
- SCHEDULE 13D Stake Beneficial Ownership Report
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Open-market buy Director bought 625,000 shares at $16.00 ($10,000,000)
- 4 Open-market buy Director bought 625,000 shares at $16.00 ($10,000,000)
- 4 Open-market buy Director bought 6,000 shares at $16.00 ($96,000)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 312,500 shares at $16.00 ($5,000,000)
- 4 Conversion Director acquired 578,524 shares (conversion)
- 4 Open-market buy Chief Financial Officer bought 700 shares at $16.00 ($11,200)
- 4 Open-market buy General Counsel bought 4,700 shares at an average $15.89 ($74,700)
- 4 Derivatives Options or other derivatives
- 4 Conversion Executive Chairman acquired 1,838,896 shares (conversion)
- 4 Conversion President and CEO acquired 1,838,896 shares (conversion)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Bylaws or fiscal year change · Other events
Page 1 of 3 · 44 filings